In short
This article explores the use of Encorafenib, a BRAF inhibitor, in various clinical trials for the treatment of different types of cancer. Encorafenib has shown promise in targeting tumors with BRAF mutations, particularly in melanoma, colorectal cancer, and non-small cell lung cancer. The trials aim to evaluate the drug's efficacy, safety, and optimal dosing strategies, both as a single agent and in combination with other therapies.
At a glance
- Drug Name
- Encorafenib (also known as LGX818, Braftovi)
- Drug Class
- BRAF inhibitor
- Target Cancers
- Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer, other BRAF V600 mutant solid tumors
- Common Combinations
- Binimetinib (MEK inhibitor), Cetuximab, FOLFIRI chemotherapy
- Dosage Forms
- Oral capsules (typically 50mg, 75mg, or 100mg)
- Typical Dosing
- 300mg once daily, with variations based on specific trial protocols
- Key Outcome Measures
- Overall Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS), Duration of Response (DOR)
- Safety Monitoring
- Adverse events, laboratory abnormalities, ECG changes, vital signs
- Pharmacokinetic Assessments
- Plasma concentration, AUC, Cmax, Tmax, half-life
- Trial Phases
- Phase I, II, and III studies represented
What is Encorafenib?
Encorafenib is a targeted cancer therapy drug used to treat certain types of cancers. It is also known by its brand name Braftovi and other names like PF-07263896, LGX818, ONO-7702, and W0090. Encorafenib belongs to a class of drugs called BRAF inhibitors, which work by targeting a specific genetic mutation in cancer cells.
How Encorafenib Works
Encorafenib works by targeting a specific genetic mutation called BRAF V600. This mutation is found in some types of cancer cells and causes them to grow and divide uncontrollably. By blocking the effects of this mutation, encorafenib can help slow down or stop the growth of cancer cells.
The BRAF V600 mutation affects a pathway in cells called the MAPK pathway. This pathway is like a communication system that tells cells when to grow and divide. When there's a mutation in the BRAF gene, it's like the "off switch" for this pathway is broken, causing cells to grow out of control. Encorafenib helps fix this by turning off the faulty signal.
Conditions Treated with Encorafenib
Encorafenib is used to treat several types of cancers that have the BRAF V600 mutation, including:
- Melanoma: This is a type of skin cancer. Encorafenib is used to treat advanced melanoma (melanoma that has spread to other parts of the body) or melanoma that can't be removed by surgery.
- Colorectal Cancer: Encorafenib is also used to treat advanced colorectal cancer (cancer of the colon or rectum) that has spread to other parts of the body.
- Non-Small Cell Lung Cancer (NSCLC): Some studies are looking at using encorafenib to treat this type of lung cancer when it has the BRAF V600 mutation.
Combination Therapies
Encorafenib is often used in combination with other drugs to make the treatment more effective. Some common combinations include:
- Encorafenib + Binimetinib: This combination is used to treat melanoma. Binimetinib is another targeted therapy that works together with encorafenib to block cancer cell growth.
- Encorafenib + Cetuximab: This combination is used to treat colorectal cancer. Cetuximab is a type of drug called a monoclonal antibody that helps the immune system fight cancer cells.
- Encorafenib + Binimetinib + Cetuximab: This triple combination is being studied for colorectal cancer to see if it's more effective than other treatments.
Administration and Dosing
Encorafenib is taken orally (by mouth) as a capsule. The typical dose is 300 mg once daily, but this can vary depending on the specific condition being treated and whether it's being used alone or in combination with other drugs. It's important to take encorafenib exactly as prescribed by your doctor.
Side Effects and Safety
Like all medications, encorafenib can cause side effects. Common side effects may include:
- Fatigue (feeling tired)
- Nausea or vomiting
- Abdominal pain
- Skin reactions (such as rash or itching)
- Joint pain
- Changes in liver function tests
Your healthcare team will monitor you closely for side effects and may adjust your dose if needed. It's important to report any side effects you experience to your doctor.
Ongoing Research
Researchers are continually studying encorafenib to learn more about its effectiveness and safety. Some areas of ongoing research include:
- Using encorafenib in combination with other drugs to treat different types of cancers.
- Studying how encorafenib affects patients with liver problems.
- Looking at using encorafenib earlier in the course of cancer treatment.
- Investigating the use of encorafenib in patients whose cancer has returned after previous treatments.
These ongoing studies help doctors understand how to use encorafenib more effectively and safely to treat cancer patients.